Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, Vol 25, No 26 (September 10), 2007: pp. 4033-4042
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.11.3985

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duda, D. G.
Right arrow Articles by Willett, C. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duda, D. G.
Right arrow Articles by Willett, C. G.

REVIEW ARTICLE

Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers

Dan G. Duda, Rakesh K. Jain, Christopher G. Willett

From the Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA; and the Department of Radiation Oncology, Duke University Medical Center, Durham, NC

Address reprint requests to Christopher G. Willett, MD, Box 3085, Duke University Medical Center, Durham, NC 27710; e-mail: christopher.willett{at}duke.edu or Dan G. Duda, DMD, PhD, Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom St, Cox-734, Boston, MA 02114; e-mail: duda{at}steele.mgh.harvard.edu

Although still in very early stages of clinical development, the combination of antiangiogenics with contemporary chemoradiotherapy regimens has emerged as a feasible and promising approach to many cancers. We review the rationale and the current understanding of antiangiogenics and their therapeutic potential in combination with chemoradiotherapy. Finally, we offer a perspective on future research directions aimed at making this complex therapeutic approach successful in the clinic.

Supported by National Cancer Institute Grants No. R21 CA099237 (to C.G.W.) and P01 CA80124 and R01 CA115767 (to R.K.J.), a National Foundation for Cancer Research Grant (to R.K.J.) and an American Association for Cancer Research–Genentech BioOncology Career Development Award (to D.G.D.).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article




This article has been cited by other articles:


Home page
Cancer Res.Home page
S. P. Dineen, K. D. Lynn, S. E. Holloway, A. F. Miller, J. P. Sullivan, D. S. Shames, A. W. Beck, C. C. Barnett, J. B. Fleming, and R. A. Brekken
Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration into Orthotopic Pancreatic Tumors in Mice
Cancer Res., June 1, 2008; 68(11): 4340 - 4346.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
N. A.J.B. Peters, D. J. Richel, J. J.C. Verhoeff, and L. J.A. Stalpers
Bowel Perforation After Radiotherapy in a Patient Receiving Sorafenib
J. Clin. Oncol., May 10, 2008; 26(14): 2405 - 2406.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online